AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.06
-0.16 (-1.17%)
As of 3:14PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close13.22
Open13.15
Bid13.01 x 2200
Ask13.02 x 800
Day's Range12.92 - 13.36
52 Week Range10.76 - 33.63
Volume1,267,152
Avg. Volume2,387,833
Market Cap1.639B
Beta1.56
PE Ratio (TTM)N/A
EPS (TTM)-1.48
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target Est27.25
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding AKRX is favorable, with net inflows of $7.73 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Is Akorn (AKRX) a Suitable Stock for Value Investors Now?
    Zacks11 days ago

    Is Akorn (AKRX) a Suitable Stock for Value Investors Now?

    Let's see if Akorn, Inc. (AKRX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

  • AKRX vs. AMPH: Which Stock Should Value Investors Buy Now?
    Zacks11 days ago

    AKRX vs. AMPH: Which Stock Should Value Investors Buy Now?

    AKRX vs. AMPH: Which Stock Is the Better Value Option?

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Akorn Enters Oversold Territory
    Zacks27 days ago

    Akorn Enters Oversold Territory

    Akorn has been on a bit of a cold streak lately.

  • AKRX vs. AMPH: Which Stock Should Value Investors Buy Now?
    Zacks28 days ago

    AKRX vs. AMPH: Which Stock Should Value Investors Buy Now?

    AKRX vs. AMPH: Which Stock Is the Better Value Option?

  • Do Options Traders Know Something About Akorn (AKRX) Stock We Don't?
    Zacks28 days ago

    Do Options Traders Know Something About Akorn (AKRX) Stock We Don't?

    Investors in Akorn (AKRX) need to pay close attention to the stock based on moves in the options market lately.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Akorn

    NEW YORK, NY / ACCESSWIRE / August 24, 2018 / U.S. markets plunged on Thursday following the release of the minutes from the latest Federal Reserve meeting, which called for an interest hike in September. ...

  • Here's Why Akorn, Inc. Fell as Much as 24.1% Today
    Motley Foollast month

    Here's Why Akorn, Inc. Fell as Much as 24.1% Today

    The rift with Fresenius continues to make headlines.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • RBC Is Bullish on Generic Pharma: Upgrades MYL, AMRX, ENDO, AKRX
    Market Realistlast month

    RBC Is Bullish on Generic Pharma: Upgrades MYL, AMRX, ENDO, AKRX

    RBC Is Bullish on Generic Pharma: Upgrades MYL, AMRX, ENDO, AKRXRBC updates its view on the generic pharma industry

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • GlobeNewswire2 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics — New Research Emphasizes Economic Growth

    NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Five ...

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks

    WallStEquities.com revisits the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. Under assessment this morning are these four stocks: Agile Therapeutics Inc. (NASDAQ: AGRX), Akorn Inc. (NASDAQ: AKRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX).

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Aurora Cannabis and Akorn

    NEW YORK, NY / ACCESSWIRE / July 30, 2018 / U.S. markets plunged on Friday, after Twitter reported disappointing second quarter earnings and gross domestic product reflected fairly strong economic growth, ...

  • ACCESSWIRE2 months ago

    Oversold Biotechnology Companies

    Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential HENDERSON, NV / ACCESSWIRE / ...

  • Akorn Fell 6.8% on July 13, Fresenius-Akorn Merger Woes Continue
    Market Realist2 months ago

    Akorn Fell 6.8% on July 13, Fresenius-Akorn Merger Woes Continue

    On July 13, Akorn (AKRX) shares fell ~6.8% and closed at $17.91. Currently, Akorn stock is trading higher than its 50-day moving average of $15.83, while the stock is trading lower than its 200-day moving average of $21.04. According to Mats Henriksson, chief executive of a Fresenius unit, Fresenius spent two years addressing the problems with one of its plants in India.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding AKRX totaled $640 million.

  • Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session
    Zacks2 months ago

    Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session

    Akorn (AKRX) was a big mover last session, as the company saw its shares rise more than 7% on the day, amid huge volumes.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Akorn and Momenta Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 13, 2018 / U.S. markets made it in the green on Thursday, pushed higher by rally in information technology and telecom stocks, covering continued uncertainty over trade ...

  • Fresenius Had Testing Woes Similar to Akorn, Unit Head Says
    Bloomberg2 months ago

    Fresenius Had Testing Woes Similar to Akorn, Unit Head Says

    A Fresenius SE executive acknowledged his company has grappled with testing problems similar to those the German health-care company cited as a basis for pulling out of a $4.3 billion deal to buy U.S. generic drugmaker Akorn Inc. Mats Henriksson, chief executive of a Fresenius unit, testified Thursday that U.S. Food and Drug Administration inspectors in 2013 questioned drug-injection testing and test-result storage at one of the firm’s plants in India. It took the company two years to address those problems, Henriksson told Delaware Chancery Judge Travis Laster.

  • Execution blocked after company objects to use of its drug
    Associated Press2 months ago

    Execution blocked after company objects to use of its drug

    A twice-convicted killer who wants to die rather than spend his life in prison was about an hour from eating his final meal Wednesday when he found out a Nevada judge had indefinitely delayed his execution after a pharmaceutical company objected to the use of one of its drugs to put someone to death. Instead of carrying out what would have been the first execution in Nevada since 2006 and the first in the U.S. using an untried combination of three drugs, state officials must now reassess their options. Scott Raymond Dozier, 47, was put on suicide watch as a precaution while officials planned a psychological evaluation at the state prison in the remote northeastern city of Ely before he returns to death row.